Revenue

Rail Vision just secured a key European patent for its AI collision avoidance tech. Is this IP fortress enough to challenge giants and define the future of rail?

AMTD Digital's subsidiary is on a global hotel buying binge, but a history of extreme stock volatility and underlying financial risks raise serious questions.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

The hiring of M&A veteran Eric Olson as Chief Corporate Development Officer signals REI Systems’ aggressive new strategy to conquer the national security market.

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

MCF Advisors' acquisition of AWM, its first since a major PE investment, pushes its AUM to $3.9B and showcases the playbook reshaping regional wealth.

The SKIPPY and Milk Bar partnership reveals more than a secret recipe; it’s a masterclass in turning supply chain logistics into brand equity.

A decade after his passing, a hyper-exclusive David Bowie tribute redefines luxury, blending musical authenticity with bespoke hospitality for a new class of investor.

Quipt Home Medical's acquisition by private equity offers a massive premium to shareholders and sets the stage for aggressive M&A in the home respiratory care market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

Talen Energy unveils a major executive overhaul and a novel compensation plan, signaling a strategic pivot to dominate the energy-hungry AI data center market.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.